https://www.selleckchem.com/pr....oducts/skf38393-hcl.
of any two regimens with different rankings provides strong evidence for selecting optimal first-line ICIs according to patients' clinical characteristics. A combination of ICIs with chemotherapy, rather than double ICIs, is the best first-line treatment for advanced wild-type NSCLC, with synergy that leads to better long-term survival. The panoramic view of the relative efficacy of any two regimens with different rankings provides strong evidence for selecting optimal first-line ICIs according to patients' clinical characteristics
Like
Comment
Share
